What Is the Half-Life of Retatrutide? The Pharmacokinetic Story

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Retatrutide's half-life is approximately 6 days based on Phase 1 pharmacokinetic data, supporting once-weekly subcutaneous dosing
• This sits between tirzepatide (about 5 days) and semaglutide (about 7 days). All three peptides use the same fatty acid acylation strategy to extend half-life
• The long half-life is engineered, not incidental. The fatty acid side chain binds to circulating albumin, which protects the peptide from rapid renal clearance and enzymatic breakdown
• Steady state in plasma is reached after approximately 4-5 weekly doses, which is why clinical titration schedules often hold each dose level for several weeks
• Retatrutide is investigational and not FDA-approved. FormBlends does not supply retatrutide

Direct answer

Retatrutide has a plasma half-life of approximately 6 days based on Phase 1 pharmacokinetic studies. This places it between tirzepatide (around 5 days) and semaglutide (around 7 days). The long half-life is engineered through fatty acid acylation that promotes binding to circulating albumin, the most abundant plasma protein. Albumin binding shields the peptide from rapid renal clearance and proteolytic degradation, extending the time the drug remains active in circulation. The 6-day half-life is what makes once-weekly subcutaneous dosing pharmacologically appropriate. Retatrutide is investigational; FormBlends does not supply it.

Table of contents

1. What "half-life" means in pharmacokinetics
2. The Phase 1 data on retatrutide
3. Why 6 days (the molecular engineering story)
4. The half-life comparison across the GLP-1 family
5. How half-life determines dosing frequency
6. Time to steady state and the titration implication
7. The wash-out period after stopping
8. Renal and hepatic considerations
9. What this means clinically
10. FAQ
11. Sources

What "half-life" means in pharmacokinetics

The plasma half-life of a drug is the time required for the plasma concentration to fall by 50%. It is a fundamental pharmacokinetic parameter that describes how quickly the body clears the drug.

For a drug with a 6-day half-life:

• At 6 days after a single dose, plasma concentration is 50% of peak
• At 12 days, concentration is 25% of peak
• At 18 days, concentration is 12.5% of peak
• At 24 days, concentration is 6.25% of peak
• At 30 days (five half-lives), concentration is roughly 3% of peak, which is the conventional threshold for considering the drug essentially eliminated

Half-life is determined by two factors: the volume of distribution (how widely the drug spreads through body tissues) and the clearance rate (how quickly elimination pathways remove it). Drugs engineered for long half-life typically have both modest volume of distribution (kept primarily in plasma through protein binding) and slow clearance (resistant to standard renal and enzymatic elimination pathways).

The Phase 1 data on retatrutide

Phase 1 pharmacokinetic studies for retatrutide established the dose-response and half-life parameters that informed later clinical development. Published Phase 1 and Phase 2 reports (Coskun et al. 2022; Jastreboff et al. 2023) describe single-ascending-dose and multiple-ascending-dose pharmacokinetics consistent with a half-life of approximately 6 days across the dose range studied.

Key Phase 1 observations:

• Linear pharmacokinetics across the dose range tested, meaning plasma concentrations scale proportionally with dose
• Time to peak plasma concentration approximately 24-72 hours after subcutaneous injection
• Half-life approximately 6 days, supporting once-weekly dosing
• No significant accumulation beyond predicted steady-state levels with weekly dosing
• Inter-individual variability in pharmacokinetic parameters comparable to other GLP-1 family peptides

The 6-day half-life finding was an explicit design target. Eli Lilly's medicinal chemistry team engineered retatrutide with the same fatty acid acylation strategy used in semaglutide and tirzepatide specifically to achieve a half-life supporting weekly dosing.

Why 6 days (the molecular engineering story)

Native peptide hormones in the human body have very short half-lives. Endogenous GLP-1 has a half-life of about 2 minutes; native GIP about 7 minutes; native glucagon about 5 minutes. These hormones are designed to act briefly and clear quickly, regulated by enzymes like dipeptidyl peptidase-4 (DPP-4) that rapidly degrade them.

A drug with a 2-minute half-life would require continuous infusion to maintain therapeutic levels. That is not practical for chronic outpatient therapy. The medicinal chemistry challenge for the GLP-1 family was to engineer molecules that retain receptor activity but extend half-life by orders of magnitude.

The solution converged on fatty acid acylation. Specifically:

• Attach a long-chain fatty acid to one amino acid residue of the peptide
• The fatty acid promotes reversible binding to circulating albumin
• Albumin has a half-life of approximately 19 days in plasma
• While bound to albumin, the peptide is protected from rapid renal filtration (too large to filter when albumin-bound) and from DPP-4 cleavage (the binding site is modified to resist the enzyme)
• The peptide cycles between albumin-bound and free states, with the free state being the receptor-active fraction

This strategy was pioneered with insulin detemir (NPH-replacement basal insulin) and refined for GLP-1 with semaglutide. Tirzepatide and retatrutide use the same approach with their own specific fatty acid chemistries.

The 6-day half-life for retatrutide is roughly one-third of albumin's half-life, which is consistent with a drug that spends most of its plasma time bound to albumin. The free-drug fraction is small at any given moment but constantly replenished from the albumin-bound pool.

The half-life comparison across the GLP-1 family

Molecule	Receptor activity	Plasma half-life	Dosing frequency
Native GLP-1	GLP-1 only	~2 minutes	Continuous infusion only
Exenatide (short-acting)	GLP-1 only	~2.4 hours	Twice daily
Liraglutide	GLP-1 only	~13 hours	Daily
Semaglutide	GLP-1 only	~7 days	Weekly
Tirzepatide	GLP-1 and GIP	~5 days	Weekly
Retatrutide	GLP-1, GIP, glucagon	~6 days	Weekly

The progression from short-acting to long-acting in this family tracks the evolution of fatty acid acylation chemistry. Each generation added stability while preserving receptor binding. The weekly-dosing peptides (semaglutide, tirzepatide, retatrutide) all sit in the 5-7 day half-life range, which is the sweet spot for once-weekly therapy.

Retatrutide's triple-receptor activity (GLP-1, GIP, glucagon) does not affect the half-life directly. The fatty acid acylation strategy operates independently of which receptors the peptide engages. The added glucagon receptor activity contributes to the higher weight loss outcomes seen in retatrutide Phase 2 (approximately 22.1% mean weight reduction at 12 mg over 48 weeks in Jastreboff et al. 2023) without changing the pharmacokinetic profile substantially.

How half-life determines dosing frequency

A general pharmacokinetic principle: dosing interval should be at or below the drug's half-life for relatively stable plasma levels. The fluctuation between peak and trough concentrations during steady-state dosing depends on the ratio of dosing interval to half-life.

For retatrutide with a 6-day half-life:

• Daily dosing: minimal fluctuation, but excessive accumulation (concentrations would build to many times the single-dose peak)
• Weekly dosing (interval roughly equals half-life): fluctuation around 2x between peak and trough, steady state after ~5 weeks. This is the standard
• Twice-monthly dosing: fluctuation around 4x between peak and trough, more variable clinical effect
• Monthly dosing: too long an interval; concentrations would dip to subtherapeutic levels between doses

The weekly interval is the practical compromise. It balances pharmacokinetic stability (acceptable peak-to-trough fluctuation), patient adherence (weekly is more memorable than daily), and clinical convenience.

Time to steady state and the titration implication

For any drug, time to steady state plasma concentration is approximately 4-5 half-lives. For retatrutide with a 6-day half-life:

• After 1 week of weekly dosing: plasma levels at approximately 50% of eventual steady state
• After 2 weeks: approximately 75%
• After 3 weeks: approximately 87.5%
• After 4 weeks: approximately 93%
• After 5 weeks: approximately 97%, essentially at steady state

This is why clinical titration schedules typically hold each dose level for at least four weeks before escalating. The full effect of a given dose is not apparent until plasma levels stabilize, and rushing escalation risks compounding side effects from incomplete dose equilibration with the side effects of dose increase.

The Phase 2 trial dose ladder (1, 4, 8, 12 mg weekly per Jastreboff et al. 2023) used 4-week intervals between dose escalations, consistent with this pharmacokinetic logic.

The wash-out period after stopping

After a final dose, plasma concentrations decline with the same half-life kinetics. For retatrutide:

• 1 week after last dose: 50% of last-dose peak remains
• 2 weeks: 25%
• 3 weeks: 12.5%
• 4 weeks: 6.25%
• 5 weeks: 3.125%, essentially eliminated

This wash-out timeline is relevant for several clinical scenarios:

• Switching to a different GLP-1 family medication: the residual retatrutide effect persists for weeks after discontinuation, which affects when to introduce the new agent
• Pregnancy planning: GLP-1 family medications are generally discontinued before conception. The wash-out timeline informs how far in advance to stop
• Surgery: some clinicians recommend holding GLP-1 medications before surgery due to delayed gastric emptying concerns; the half-life affects how far in advance this needs to occur
• Weight regain after discontinuation: the gradual decline in plasma levels produces a gradual return of appetite over the first month rather than an abrupt change

Renal and hepatic considerations

Albumin-bound peptides like retatrutide are primarily eliminated through proteolytic catabolism rather than direct renal filtration of intact drug. The fatty acid acylation prevents the small free-drug fraction from being filtered at normal kidney function levels.

That said, peptide drugs in this class show some prolongation of half-life in patients with severe renal impairment, based on pharmacokinetic studies of semaglutide and tirzepatide in patients with reduced kidney function. Retatrutide-specific renal-impairment data will emerge from Phase 3 studies. Trial protocols typically exclude patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or monitor them closely.

Hepatic impairment has minimal effect on peptide pharmacokinetics in this class, because the liver is not a major site of peptide clearance.

Drug interactions through cytochrome P450 enzymes are also minimal for peptide drugs, because peptides are not metabolized by CYP enzymes. This is a meaningful advantage for the GLP-1 family compared to small-molecule drugs that often have extensive CYP-mediated drug interactions.

What this means clinically

The 6-day half-life shapes nearly every aspect of how retatrutide would be used clinically if it reaches approval:

• Weekly subcutaneous dosing is the natural fit, consistent with semaglutide and tirzepatide
• Titration schedules need 4-week dose levels to allow for steady-state equilibration before escalating
• Clinical effect onset at a new dose takes several weeks; patients shouldn't expect immediate change after a dose increase
• Discontinuation effects persist for approximately a month, both in terms of remaining drug effect and the gradual return of appetite signals
• Pre-procedure holds (surgery, pregnancy planning) need to account for the long wash-out period
• Missed doses are forgiving: a single missed weekly dose drops plasma levels but does not eliminate the drug; the next dose effectively re-equilibrates the system

The pharmacokinetic profile is what enables the weekly-dose-and-forget convenience that distinguishes this generation of obesity therapeutics from earlier daily-dose options. The 6-day half-life is not a minor technical detail; it is the design feature that defines the clinical experience.

FAQ

What is the half-life of retatrutide? Approximately 6 days based on Phase 1 pharmacokinetic studies. This supports once-weekly subcutaneous dosing. Retatrutide is investigational; FormBlends does not supply it.

Why does retatrutide have such a long half-life? Fatty acid acylation promotes binding to albumin, which protects the peptide from rapid renal clearance and enzymatic degradation. The same strategy is used in semaglutide and tirzepatide.

How does retatrutide half-life compare to semaglutide and tirzepatide? Retatrutide approximately 6 days, tirzepatide approximately 5 days, semaglutide approximately 7 days. All three support weekly dosing.

Why does the half-life support weekly dosing? A 6-day half-life produces approximately 2x peak-to-trough fluctuation with weekly intervals, which is clinically acceptable for chronic therapy.

How long does retatrutide stay in your system? Approximately 5 half-lives (30 days) for essentially complete elimination after a final dose. Effects fade gradually over that month.

Does retatrutide reach steady state in plasma? Yes, after approximately 4-5 weekly doses. This is why titration schedules hold each dose level for several weeks before escalating.

Does kidney function affect retatrutide half-life? Severe renal impairment may prolong the half-life of related GLP-1 family peptides. Retatrutide-specific renal-impairment data will emerge from Phase 3 studies.

Why does the half-life matter clinically? It determines dosing frequency (weekly), time to steady state (4-5 weeks), and wash-out period after stopping (about a month). These shape both efficacy onset and discontinuation planning.

What happens if I miss a weekly retatrutide dose? With a 6-day half-life, a single missed dose causes plasma levels to drop by approximately 50% before the next dose. The system re-equilibrates over the next 2-3 doses. Missed doses are not catastrophic but should be reported to the prescriber.

Does retatrutide accumulate over months of dosing? Plasma levels rise from baseline over the first 4-5 weeks, then stabilize at steady state. No further accumulation occurs at a constant dose. Dose increases trigger a new equilibration period.

Related guides

• Why Retatrutide Is Dosed Once Weekly: Half-Life and Trial Design
• Is Retatrutide a GLP-1? Sort of, But That's Not the Whole Story
• Retatrutide and Quality of Life Improvements
• Retatrutide at 6 Months: Half-Year Progress

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
2. Coskun T, Urva S, Roell WC, et al. LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept. Cell Metabolism. 2022;34(9):1234-1247.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. FDA Prescribing Information: Ozempic (semaglutide injection). Novo Nordisk. Updated 2024.
6. FDA Prescribing Information: Mounjaro (tirzepatide injection). Eli Lilly. Updated 2024.
7. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019;10:155.
8. Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.
9. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept. Molecular Metabolism. 2018;18:3-14.
10. Urva S, Coskun T, Loh MT, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist in People with Type 2 Diabetes: A Phase 1b, Multicentre, Double-Blind, Placebo-Controlled, Randomised, Multiple-Ascending Dose Trial. The Lancet. 2022;400(10366):1869-1881.
11. Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism. 2018;27(4):740-756.
12. Eli Lilly and Company. Pipeline Disclosure: Retatrutide Phase 3 Trials. SEC filings 2024-2025.

Footer disclaimers

Platform Disclaimer. FormBlends operates a digital health platform that connects patients to U.S.-licensed providers and state-licensed pharmacies. We do not manufacture, prescribe, or dispense medication. We do not sell or supply retatrutide. All clinical decisions belong to the patient and an independent licensed prescriber.

Compounded Medication Notice. Compounded medications from state-licensed 503A pharmacies follow USP 797 standards but are not FDA-approved. They have not undergone the agency review applied to brand-name drugs and are not interchangeable with FDA-approved products.

Results Disclaimer. Pharmacokinetic data described here are drawn from published Phase 1 and Phase 2 reports. Retatrutide is investigational; Phase 3 data may refine the half-life and dose-response parameters as additional patients are studied. Clinical outcomes vary by individual.

Trademark Notice. Retatrutide is the developmental designation for an investigational compound from Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with the named companies.